Literature DB >> 21940055

Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission.

Stephanie Knippenberg1, Evelyn Peelen, Joost Smolders, Mariëlle Thewissen, Paul Menheere, Jan Willem Cohen Tervaert, Raymond Hupperts, Jan Damoiseaux.   

Abstract

In this study, we assessed B cell subsets, including Bregs, during stable and active disease in relapsing remitting multiple sclerosis (RRMS) patients and related B cell subsets to vitamin D status. We report that RRMS patients have a decreased percentage of both memory B cells and Bregs compared to healthy controls. During a relapse, the reduction in Bregs involved in particular naïve Bregs. We found no correlation between vitamin D status and B cell subsets. An effect of vitamin D on Bregs cannot be ruled out, since it might be the function that is interfered with instead of relative numbers. Copyright Â
© 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940055     DOI: 10.1016/j.jneuroim.2011.08.019

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  66 in total

Review 1.  Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Authors:  Arya Biragyn; Maria Aliseychik; Evgeny Rogaev
Journal:  Semin Immunopathol       Date:  2017-01-12       Impact factor: 9.623

2.  Circulating regulatory B cell subsets in patients with neuromyelitis optica spectrum disorders.

Authors:  Jinming Han; Li Sun; Zhongkun Wang; Xueli Fan; Lifang Wang; Yang-Yang Song; Jie Zhu; Tao Jin
Journal:  Neurol Sci       Date:  2017-04-07       Impact factor: 3.307

Review 3.  Circulating immune cells in multiple sclerosis.

Authors:  A P Jones; A G Kermode; R M Lucas; W M Carroll; D Nolan; P H Hart
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

4.  CD19+ Tim-1+ B cells are decreased and negatively correlated with disease severity in Myasthenia Gravis patients.

Authors:  Yong Zhang; Xiuying Zhang; Yan Xia; Xiao Jia; Hao Li; Yanyan Zhang; Zhen Shao; Ning Xin; Mingfeng Guo; Jing Chen; ShuangShuang Zheng; YuZhong Wang; Linlin Fu; Chenghua Xiao; Deqin Geng; Yonghai Liu; Guiyun Cui; Ruiguo Dong; Xiaoyu Huang; Tingyan Yu
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

5.  Mesenchymal stromal cells attenuate multiple sclerosis via IDO-dependent increasing the suppressive proportion of CD5+ IL-10+ B cells.

Authors:  Huijuan Li; Yinan Deng; Jinliang Liang; Feng Huang; Wei Qiu; Min Zhang; Youming Long; Xueqiang Hu; Zhengqi Lu; Wei Liu; Song Guo Zheng
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 6.  Human regulatory B cells in health and disease: therapeutic potential.

Authors:  Claudia Mauri; Madhvi Menon
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

Review 7.  The Immunologic Paradoxes of IgG4-Related Disease.

Authors:  Xiao Xiao; Min Lian; Weici Zhang; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

8.  Frequency and immunophenotype of IL10-producing regulatory B cells in optic neuritis.

Authors:  Sara Lundqvist; Signe Modvig; Emilie A Fischer; Jette L Frederiksen; Matilda Degn
Journal:  Immunology       Date:  2018-12-27       Impact factor: 7.397

Review 9.  Gut commensalism, cytokines, and central nervous system demyelination.

Authors:  Kiel Telesford; Javier Ochoa-Repáraz; Lloyd H Kasper
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

10.  B-cell targeting agents in the treatment of multiple sclerosis.

Authors:  Tiffany J Braley; Benjamin M Segal
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.